JP2009539890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539890A5 JP2009539890A5 JP2009514643A JP2009514643A JP2009539890A5 JP 2009539890 A5 JP2009539890 A5 JP 2009539890A5 JP 2009514643 A JP2009514643 A JP 2009514643A JP 2009514643 A JP2009514643 A JP 2009514643A JP 2009539890 A5 JP2009539890 A5 JP 2009539890A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound according
- addition salt
- compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000002193 Pain Diseases 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 9
- 208000004296 neuralgia Diseases 0.000 claims 5
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 229960005261 aspartic acid Drugs 0.000 claims 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- LTHLADNMDHIVEZ-UHFFFAOYSA-N 4-[2-(4-methylphenyl)sulfanylphenyl]piperidine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 LTHLADNMDHIVEZ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000001387 Causalgia Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010057254 Connective tissue inflammation Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016825 Flushing Diseases 0.000 claims 1
- 206010056465 Food craving Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000029549 Muscle injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000020307 Spinal disease Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- CVASBKDYSQKLSO-UHFFFAOYSA-N Tedatioxetine Chemical compound C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 CVASBKDYSQKLSO-UHFFFAOYSA-N 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229960000448 lactic acid Drugs 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- -1 salt monohydrate Chemical class 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80500906P | 2006-06-16 | 2006-06-16 | |
| US60/805,009 | 2006-06-16 | ||
| DKPA200600816 | 2006-06-16 | ||
| DKPA200600816 | 2006-06-16 | ||
| DKPA200700423 | 2007-03-20 | ||
| DKPA200700423 | 2007-03-20 | ||
| PCT/DK2007/050076 WO2007144006A1 (en) | 2006-06-16 | 2007-06-15 | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013122095A Division JP5650280B2 (ja) | 2006-06-16 | 2013-06-10 | 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539890A JP2009539890A (ja) | 2009-11-19 |
| JP2009539890A5 true JP2009539890A5 (enExample) | 2011-08-04 |
| JP5318757B2 JP5318757B2 (ja) | 2013-10-16 |
Family
ID=38434468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009514643A Expired - Fee Related JP5318757B2 (ja) | 2006-06-16 | 2007-06-15 | 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形 |
| JP2013122095A Expired - Fee Related JP5650280B2 (ja) | 2006-06-16 | 2013-06-10 | 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013122095A Expired - Fee Related JP5650280B2 (ja) | 2006-06-16 | 2013-06-10 | 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US8299095B2 (enExample) |
| EP (1) | EP2044020B1 (enExample) |
| JP (2) | JP5318757B2 (enExample) |
| AU (1) | AU2007260356B2 (enExample) |
| CA (1) | CA2656057C (enExample) |
| CY (1) | CY1111619T1 (enExample) |
| EA (1) | EA016054B1 (enExample) |
| HR (1) | HRP20110412T1 (enExample) |
| IL (1) | IL195310A (enExample) |
| MA (1) | MA30576B1 (enExample) |
| MX (1) | MX2008016008A (enExample) |
| NO (1) | NO20090250L (enExample) |
| PL (1) | PL2044020T3 (enExample) |
| WO (1) | WO2007144006A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20110412T1 (hr) * | 2006-06-16 | 2011-06-30 | H. Lundbeck A/S | Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova |
| DK2044020T3 (da) * | 2006-06-16 | 2011-08-15 | Lundbeck & Co As H | Krystallinske former af 4-[2-(4-methylphenylsulfanyl)-phenyl]-piperidin med kombineret serotonin- og norepinephrin-genoptagelsesinhibering til behandling af neuropatisk smerte |
| EP2439201B1 (en) | 2006-06-16 | 2013-08-07 | H. Lundbeck A/S | Compounds with combined sert, 5-ht3 and 5-ht1a activity |
| TWI432194B (zh) | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途 |
| TWI405588B (zh) | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物 |
| JP5764327B2 (ja) * | 2007-06-15 | 2015-08-19 | ハー・ルンドベック・アクチエゼルスカベット | 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン |
| TW200938194A (en) * | 2007-12-14 | 2009-09-16 | Lundbeck & Co As H | Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter |
| UA98698C2 (en) | 2008-03-03 | 2012-06-11 | Х. Луннбек А/С | Phenylsulfanylphenyl-piperidines and process for the preparation thereof |
| TW201033181A (en) * | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
| HRP20140880T1 (hr) * | 2009-04-24 | 2014-11-07 | H. Lundbeck A/S | Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina |
| MX2011011579A (es) * | 2009-04-30 | 2012-01-27 | Supernus Pharmaceuticals Inc | Metodo de tratamiento contra la depresion. |
| US8920840B2 (en) * | 2010-04-30 | 2014-12-30 | Takeda Pharmaceutical Company Limited | Enteric tablet |
| BR112018003930A2 (pt) | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| US20200048979A1 (en) | 2018-08-13 | 2020-02-13 | Saudi Arabian Oil Company | Bottomhole assembly deployment |
| CN112638526B (zh) * | 2018-08-22 | 2024-01-05 | 巴斯夫公司 | 先进的nox还原催化剂 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1084498A (en) * | 1977-05-05 | 1980-08-26 | Alexander E. Wick | Benzylpyrimidines and process for the preparation thereof |
| GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
| US7141593B1 (en) * | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
| DE60140708D1 (de) * | 2000-08-10 | 2010-01-14 | Mitsubishi Tanabe Pharma Corp | Prolinderivative und deren Verwendung als Medikamente |
| GEP20084399B (en) * | 2001-05-22 | 2008-06-10 | Pfizer Prod Inc | Crystal forms of azithromycin |
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| EP1497270A4 (en) * | 2002-03-27 | 2006-01-04 | Smithkline Beecham Corp | AMID COMPOUNDS AND METHOD FOR THEIR USE |
| US6821502B2 (en) * | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
| EP1635828B1 (en) * | 2003-04-04 | 2008-04-23 | H. Lundbeck A/S | 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| AU2004261610B2 (en) * | 2003-07-28 | 2010-05-20 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators |
| AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| AR052308A1 (es) * | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
| US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| WO2007027525A1 (en) * | 2005-08-29 | 2007-03-08 | Sanofi-Aventis U.S. Llc | Novel crystalline form of a pyridazino [4 , 5-b] indole derivative |
| EP2107066A3 (en) * | 2005-09-13 | 2009-10-21 | Sicor, Inc. | Processes for the synthesis of rocuronium bromide |
| HRP20110412T1 (hr) * | 2006-06-16 | 2011-06-30 | H. Lundbeck A/S | Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova |
| MX2009003405A (es) * | 2006-09-28 | 2009-04-09 | Merck & Co Inc | Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa. |
| US7837978B2 (en) * | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| TWI432194B (zh) * | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途 |
| CN101778855A (zh) * | 2007-05-22 | 2010-07-14 | 阿尔迪默菲克斯技术有限责任公司 | 替诺福韦酯半富马酸共晶体 |
| TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
| UA98698C2 (en) * | 2008-03-03 | 2012-06-11 | Х. Луннбек А/С | Phenylsulfanylphenyl-piperidines and process for the preparation thereof |
-
2007
- 2007-06-15 HR HR20110412T patent/HRP20110412T1/hr unknown
- 2007-06-15 PL PL07764496T patent/PL2044020T3/pl unknown
- 2007-06-15 EA EA200970019A patent/EA016054B1/ru not_active IP Right Cessation
- 2007-06-15 US US12/303,449 patent/US8299095B2/en not_active Expired - Fee Related
- 2007-06-15 WO PCT/DK2007/050076 patent/WO2007144006A1/en not_active Ceased
- 2007-06-15 AU AU2007260356A patent/AU2007260356B2/en not_active Ceased
- 2007-06-15 MX MX2008016008A patent/MX2008016008A/es active IP Right Grant
- 2007-06-15 JP JP2009514643A patent/JP5318757B2/ja not_active Expired - Fee Related
- 2007-06-15 EP EP07764496A patent/EP2044020B1/en active Active
- 2007-06-15 CA CA2656057A patent/CA2656057C/en not_active Expired - Fee Related
-
2008
- 2008-11-16 IL IL195310A patent/IL195310A/en active IP Right Grant
-
2009
- 2009-01-06 MA MA31551A patent/MA30576B1/fr unknown
- 2009-01-16 NO NO20090250A patent/NO20090250L/no not_active Application Discontinuation
-
2011
- 2011-05-13 CY CY20111100454T patent/CY1111619T1/el unknown
-
2012
- 2012-10-25 US US13/660,718 patent/US20130190352A1/en not_active Abandoned
-
2013
- 2013-06-10 JP JP2013122095A patent/JP5650280B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-14 US US14/542,210 patent/US9315459B2/en not_active Expired - Fee Related
-
2016
- 2016-03-17 US US15/072,608 patent/US20170037006A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539890A5 (enExample) | ||
| CA2656057A1 (en) | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain | |
| RU2430099C2 (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
| TWI851542B (zh) | Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑 | |
| JP2022003062A (ja) | （ｒ）−２−アミノ−３−フェニルプロピルカルバメートの溶媒和物フォーム | |
| RU2462456C2 (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| JP2009541216A5 (enExample) | ||
| JP2017510624A5 (enExample) | ||
| ES2573715T3 (es) | Ligandos sigma para la prevención y/o el tratamiento del vómito inducido por la quimioterapia o la radioterapia | |
| JP2017527578A5 (enExample) | ||
| JP4277051B2 (ja) | ５−［３−（３−ヒドロキシフェノキシ）アゼチジン−１−イル］−５−メチル−２，２−ジフェニルヘキサンアミド塩酸塩 | |
| JP2011527333A5 (enExample) | ||
| RU2018134262A (ru) | Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar | |
| WO2006006740A1 (ja) | ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤 | |
| JP2013539781A5 (enExample) | ||
| JP2012512145A5 (enExample) | ||
| JP2009040767A5 (enExample) | ||
| JP2014511897A5 (enExample) | ||
| RU2008148941A (ru) | 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции | |
| ES2665293T3 (es) | Compuesto para tratar estados con mediación alfa-adrenérgica | |
| RU2451016C2 (ru) | Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида | |
| JP2008523075A5 (enExample) | ||
| JP2010504316A (ja) | ムスカリン様受容体アンタゴニストとしてのアゼチジン誘導体 | |
| JP2019535715A5 (enExample) | ||
| JP2014506577A5 (enExample) |